Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers.
Muñoz D, Escartín A, Dapena D, Coret F, Fernández-Uría D, Pérez D, Casanova B, Guijarro-Castro C, Munteis E, Del-Campo Amigo M, et al.